Cargando…
COVID-19: Time to embrace MDI+ valved-holding chambers!
Autores principales: | Amirav, Israel, Newhouse, Michael T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242949/ https://www.ncbi.nlm.nih.gov/pubmed/32482527 http://dx.doi.org/10.1016/j.jaci.2020.04.046 |
Ejemplares similares
-
Comment on “Optimizing the Delivery of Inhaled Medication for Respiratory Patients: The Role of Valved Holding Chambers”
por: Newhouse, Michael T., et al.
Publicado: (2019) -
Asthma and COVID-19: In Defense of Evidence-Based SABA
por: Amirav, Israel, et al.
Publicado: (2020) -
In vitro performances of a valved holding chamber with inhaled corticosteroids
por: Boukhettala, Nabile, et al.
Publicado: (2015) -
PC(20) versus PD(20): Why Change a Scientifically Well-Established and Clinically Relevant Test?
por: Amirav, Israel, et al.
Publicado: (2019) -
The Bioavailability of Salbutamol in Urine via Volumatic and Nonvolumatic Valved Holding Chambers
por: Fahimi, Fanak, et al.
Publicado: (2011)